Cipher Pharmaceuticals (TSE:CPH) Share Price Passes Above 50-Day Moving Average – Time to Sell?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) shares passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$16.57 and traded as high as C$16.66. Cipher Pharmaceuticals shares last traded at C$16.46, with a volume of 26,094 shares traded.

Analyst Ratings Changes

Separately, Canaccord Genuity Group set a C$17.00 price objective on shares of Cipher Pharmaceuticals and gave the company a “hold” rating in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Cipher Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of C$17.00.

Cipher Pharmaceuticals Stock Performance

The company has a market capitalization of C$427.33 million, a PE ratio of 14.14 and a beta of 1.15. The company has a current ratio of 1.25, a quick ratio of 2.67 and a debt-to-equity ratio of 0.32. The business’s fifty day moving average is C$16.57 and its two-hundred day moving average is C$16.50.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its earnings results on Thursday, May 7th. The company reported C$0.33 EPS for the quarter. The business had revenue of C$17.39 million for the quarter. Cipher Pharmaceuticals had a return on equity of 25.69% and a net margin of 60.82%. Equities research analysts predict that Cipher Pharmaceuticals Inc. will post 1.2907348 earnings per share for the current year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.